Sabra Health Care REIT has delivered a strong 112.1% return over the past three years, and recent valuation checks now suggest the stock appears undervalued on market multiples rather than clearly expensive after that run.

• A 112.1% three-year return puts Sabra Health Care REIT among the stronger performers in its space, which raises the question of how much upside is already reflected in the price.
• Recent business updates, including re-tenanting of properties and portfolio moves that are expected to lift cash NOI, may support investors' expectations. However, any setback in executing these transitions or in senior housing operating performance remains a key risk to the valuation case.
• With a valuation score of 4 out of 6, Sabra Health Care REIT presents a mixed picture rather than a straightforward bargain or an obviously stretched stock.

The issue now is whether the current price of Sabra Health Care REIT still leaves enough valuation headroom after this multi-year rally.

Is Sabra Health Care REIT Still Cheap on Earnings?

The P/E ratio is a useful lens for Sabra Health Care REIT because earnings are a central yardstick for how efficiently the REIT is turning its property portfolio into profit. Sabra currently trades on a P/E of 35.6x, which is below both the peer group average of 44.2x and the modelled fair P/E of 39.9x for a Health Care REIT with Sabra's characteristics.

Despite the recent business update and higher 2026 guidance, the share price still implies a discount to the fair P/E level suggested by its peers and risk profile. The gap between the current 35.6x and the 39.9x fair ratio indicates that, on this earnings multiple, Sabra Health Care REIT is pricing in more caution than the tailored benchmark would suggest.

On the P/E multiple, Sabra Health Care REIT stock appears undervalued relative to its fair ratio benchmark.

The Sabra Health Care REIT Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Sabra Health Care REIT valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each Narrative treats Sabra Health Care REIT's fair value as a thesis about the business that can be revisited over time rather than a one off snapshot, and they sit on Simply Wall St's Community page.

If you have a number driven view on whether Sabra Health Care REIT's recent re tenanting plans and updated 2026 guidance ultimately deliver, share a Narrative in the Simply Wall St community and make your case explicit. It is a chance to add your voice, set out the assumptions behind your stance, and see how that thesis tracks as new results and business updates arrive.

Do you think there's more to the story for Sabra Health Care REIT? Head over to our Community to see what others are saying!

The Bottom Line

For Sabra Health Care REIT, the valuation story now rests on whether the current discount on its earnings multiple is justified by execution risk or represents mispriced caution. The market-multiple view points to an undervalued stock, but the broader checks are only mixed rather than emphatically supportive. From here, the key question is whether Sabra Health Care REIT can deliver on its portfolio plans and senior housing operating performance so that the existing multiple does not prove to be a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.